The Top 5 Biosimilar Articles for the Week of December 14

Here are the top 5 biosimilar articles for the week of December 14, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of December 14, 2020.

Number 5: Studies of trastuzumab biosimilars in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer have yielded significant findings, according to presentations at the 2020 San Antonio Breast Cancer Symposium.

Number 4: Investigators studying biosimilar savings and use rates in HER2-positive breast cancer observed dramatically increased usage of trastuzumab biosimilars and said payer policy appears to have contributed to higher biosimilar utilization.

Number 3: Celltrion’s high-concentration, citrate-free adalimumab biosimilar candidate (CT-P17, Yuflyma) has been recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Number 2: Sarfaraz K. Niazi, PhD, an advisory board member for The Center for Biosimilars, published an opinion piece on Boehringer Ingelheim’s recent filing of a citizen’s petition asking the FDA to change its interpretation of the term strength in the Public Health Service Act.

Number 1: Biocon Biologics and Mylan have received a positive recommendation from the EMA CHMP for the marketing approval of their biosimilar insulin aspart candidate (Kixelle) for the treatment of type 1 and type 2 diabetes.

To read all of these articles and more, visit centerforbiosimilars.com.